Nikolaos Grigoriadis

Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS 3:30
Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS
Nikolaos Grigoriadis • 20 Sep 2021
Current and emerging therapeutics for NMOSD 1:28
Current and emerging therapeutics for NMOSD
Nikolaos Grigoriadis • 20 Sep 2021
Relapses and progression in NMOSD and MS: understanding the underlying mechanisms 2:59
Relapses and progression in NMOSD and MS: understanding the underlying mechanisms
Nikolaos Grigoriadis • 20 Sep 2021
Is AQP4-IgG NMOSD an exclusively relapsing disease? 3:38
Is AQP4-IgG NMOSD an exclusively relapsing disease?
Nikolaos Grigoriadis • 20 Sep 2021
Differentiating NMOSD and MS 2:05
Differentiating NMOSD and MS
Nikolaos Grigoriadis • 8 Jun 2021
BTK inhibitors gain ground in MS 1:27
BTK inhibitors gain ground in MS
Nikolaos Grigoriadis • 8 Jun 2021
Tackling disease progression in MS 2:24
Tackling disease progression in MS
Nikolaos Grigoriadis • 8 Jun 2021
Horizon scanning in treating disease progression in MS 2:27
Horizon scanning in treating disease progression in MS
Nikolaos Grigoriadis • 8 Jun 2021
The content of VJNeurology is intended for healthcare professionals